Cryo-Cell International, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.6M | $32.0M | $31.3M | $30.3M | $28.9M | $31.1M | $31.8M | $29.2M |
| Cost of Revenue | $7.4M | $7.9M | $8.4M | $8.8M | $9.0M | $9.7M | $10.0M | $8.5M |
| Gross Profit | $24.2M | $24.0M | $23.0M | $21.5M | $19.9M | $21.5M | $21.8M | $20.7M |
| Gross Margin | 76.6% | 75.2% | 73.2% | 71.0% | 68.9% | 69.0% | 68.5% | 70.8% |
| Operating Expenses | ||||||||
| Research & Development | $376.3K | $1.2M | $1.2M | $384.8K | $49.9K | $23.9K | $30.1K | $91.8K |
| SG&A Expense | $18.2M | $18.5M | $17.2M | $15.6M | $14.6M | $14.3M | $14.9M | $15.6M |
| Operating Income | $482.4K | $3.5M | $-12.3M | $4.0M | $4.0M | $7.7M | $5.1M | $5.2M |
| Operating Margin | 1.5% | 10.9% | -39.3% | 13.3% | 13.9% | 24.6% | 15.9% | 17.8% |
| Interest Expense | $2.1M | $1.9M | $1.2M | $1.5M | $1.4M | $1.5M | $1.7M | $1.5M |
| Pretax Income | $-2.3M | $2.8M | $-13.4M | $3.3M | $2.6M | $5.0M | $3.4M | $3.6M |
| Income Tax Expense | $92.2K | $2.4M | $-3.8M | $547.5K | $527.7K | $1.4M | $1.1M | $4.5M |
| Net Income | $-2.4M | $402.1K | $-9.5M | $2.8M | $2.1M | $3.6M | $2.3M | $-854.8K |
| Net Margin | -7.7% | 1.3% | -30.4% | 9.1% | 7.2% | 11.6% | 7.2% | -2.9% |
| EPS (Basic) | $-0.30 | $0.05 | $-1.14 | $0.33 | $0.26 | $0.48 | $0.29 | $-0.11 |
| EPS (Diluted) | $-0.30 | $0.05 | $-1.14 | $0.33 | $0.25 | $0.45 | $0.27 | $-0.11 |
| Shares Outstanding (Basic) | 8.1M | 8.1M | 8.3M | 8.5M | 8.1M | 7.5M | 7.8M | 7.5M |
| Shares Outstanding (Diluted) | 8.1M | 8.2M | 8.3M | 8.5M | 8.4M | 8.1M | 8.4M | 7.5M |
| Dividends Per Share | — | $0.25 | — | $0.90 | — | — | — | — |